title: Dasatinib is effective against optic nerve infiltration of Philadelphia chromosome-positive acute lymphoblastic leukemia.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Satake
authors.forename: Masaya
authors.initials: M
authors.lastname: Okada
authors.forename: Takako
authors.initials: T
authors.lastname: Asada
authors.forename: Kyoko
authors.initials: K
authors.lastname: Fujita
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Ikegame
authors.forename: Hiroya
authors.initials: H
authors.lastname: Tamaki
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Fujimori
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Ogawa
mesh_terms: D000368:Aged; D000069439:Dasatinib; D005260:Female; D006801:Humans; D017254:Leukemic Infiltration / Q000188:drug therapy* / Q000473:pathology; D009900:Optic Nerve / Q000473:pathology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib